Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M

Instil Bio, Inc.

Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.
Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.
Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.
Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.
Cash expected to fund operating plan beyond 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
EPS: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
Result: reported results

Exact text from the filing

On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.